U.S. stocks are set to open higher on the final day of July. All three indexes are expected to post mild gains for the month. Futures on the Dow Jones Industrial Average…
Pfizer Inc. (NYSE: PFE) reported second-quarter adjusted earnings per share (EPS) of $0.62 and $15.06 billion in revenue this morning. Adjusted EPS was up from $0.59 in the same period a year…
Paul Ausick Last week was a jam-packed week of earnings reports and this week has many key reports. We have provided earnings previews for 11 companies we expect to follow this week. Estimates are…
The week ahead is going to be a busy week. There are many traditional events to watch, but by now the market participants and investors have learned that they have to pay…
Usually, shares of drug makers soar following the announcement that the Foood and Drug Administration approved a drug. Amarin Corp. (NASDAQ: AMRN) announced approval by the FDA for Vascepta to patients very high…
A new treatment for Alzheimer’s disease from Pfizer Inc. (NYSE: PFE) and partner Elan Corp. plc (NYSE: ELN) has failed a late-stage trial in patients with mild-to-moderate cases of the disease and…
Carlyle (NASDAQ: CG) may buy a unit of United Technologies (NYSE: UTX). (Reuters) More factories move to the United States as China’s manufacturing costs rise. (Reuters) The CEOs of Apple (NASDAQ: AAPL)…
When Gallup asked people about the state of the economy this spring, as a recovery appeared to have taken hold, the polling company found “nearly half of Americans, 46%, still say the…
Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for the first quarter of 2012. The top five sellers include drugs from…
Abbott Laboratories (NYSE: ABT) reported second-quarter results this morning that beat the consensus estimate for earnings per share (EPS), but missed slightly on revenues. The drug maker reported adjusted diluted EPS of…
What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the M&A block.…
More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in the biotech…
Some mergers are very straight-forward, and others are just odd. Now we have an answer over whether or not Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) was going to be acquired or not. Bristol-Myers…
Some products sell well when first introduced. Many more fail miserably. Very few of them sell so well that they fundamentally impact American culture. This is 24/7 Wall St.’s list of 10…
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is back in the rumor mill as far as a buyout, but this time the price appears to be more finite. We have heard enough names around…
